Correvio Pharma Corp. (CORV) Analysts See $-0.22 EPS

August 9, 2018 - By Billy Entrekin

Analysts expect Correvio Pharma Corp. (NASDAQ:CORV) to report $-0.22 EPS on August, 14.They anticipate $0.04 EPS change or 15.38 % from last quarter’s $-0.26 EPS. After having $-0.24 EPS previously, Correvio Pharma Corp.’s analysts see -8.33 % EPS growth. The stock increased 0.20% or $0.01 during the last trading session, reaching $4.9. About 8,375 shares traded. Correvio Pharma Corp. (NASDAQ:CORV) has 0.00% since August 9, 2017 and is . It has underperformed by 12.57% the S&P500.

Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. The company has market cap of $171.61 million. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. It currently has negative earnings. The company's portfolio of marketed brands include Xydalba for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm.

More notable recent Correvio Pharma Corp. (NASDAQ:CORV) news were published by: which released: “50 Biggest Movers From Yesterday” on July 31, 2018, also with their article: “Benzinga’s Biotech Pulse: Pfizer’s Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke …” published on August 01, 2018, published: “CORREVIO PHARMA CORP.” on August 07, 2018. More interesting news about Correvio Pharma Corp. (NASDAQ:CORV) were released by: and their article: “Correvio to present at the Canaccord Genuity 38th Annual Growth Conference” published on August 01, 2018 as well as‘s news article titled: “The Daily Biotech Pulse: Denali’s Parkinson’s Candidate Clears Early-Stage Trials, Dexcom’s Strong Quarter” with publication date: August 02, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.